generic-logo.png

Inflammasome Logo horizcolor

  • About
  • Target Diseases
    • Alzheimer's Disease
    • Multiple Sclerosis
    • Macular Degeneration
    • Parkinson's Disease
  • News
  • Leadership Team
  • Publications
  • Contact

News

  • New study shows multiple inflammasomes combine to cause lupus, macular degeneration and other neuroinflammatory diseases such as Alzheimer’s disease and multiple sclerosis December 2021
  • Inflammasome Therapeutics’ CEO to Be Featured Speaker at Upcoming Virtual Summit on Inflammasomes November 2021
  • Inflammasome Therapeutics’ Kamuvudines Continue to Show Promise for Future Treatment – and Potentially a Cure – for Blindness in Seniors September 2021
  • pdfInflammasome Therapeutics to Develop Dual Sustained-Release HIV Prevention and Birth Control Implant August 2021
  • Kamuvudines May be Answer to Preventing Blindness in Aging Population April 2021
  • Inflammasome Therapeutics Says Study Published Today in Proceedings of the National Academy of Sciences Provides Human Data Confirming Potential of Company’s Proprietary Compounds for Prevention of Dry AMD February - 2021
  • Inflammasome Therapeutics Says Study Approximately 130,000 People Reported in Nature Communications Points to Potential for Treatment or Prevention of Diabetes and Other Inflammasome-Mediated Diseases with Company's Drugs September - 2020
  • Inflammasome Therapeutics Receives Grant to Develop Sustained Release Bioerodible Birth Control Implant from The Gates Foundation September - 2020
  • pdfBoehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases September - 2019d
back to top

© 2019-21 Inflammasome Therapeutics

Site by Third Sun